The Molecular Cytogenetics Shared Resource (MCSR) has been in development over the last three years and was formally established as a shared resource in September 2003 to provide a wide range of cytogenetic services and investigations to the OSUCCC research community. It provides state-of-the-art molecular cytogenetic technology as well as classical banded metaphase cytogenetics. Services include metaphase karyotyping of human and mouse tissue, fluorescence in situ hybridization (FISH) using many different types of probes and tissues and multicolor spectral karyotyping (SKY). Dr. Heerema, Director of the Resource, brings a wealth of experience to the MCSR with over 25 years of experience in cytogenetics and over 135 publications. Dr. Mrozek, Associate Director of the Resource, has over 20 years of experience in cytogenetics and over 80 publications. Various specimen sources, such as human and mouse cell lines and tumor samples, paraffin embedded tissues and bone marrow or blood smears are studied, dependent on the purpose of the investigation. Services accommodate different stages of sample preparation from processing fresh tissues to preparing slides from fixed cell suspensions. Probes for FISH studies include both commercially available probes and probes developed by the MCSR. Probe development offerings include growth, amplification and labeling of the probes with different fluorophores available. The types of probes include unique-sequence DNA probes, BACs, PACs and YACs. The MCSR has been widely used by the OSUCCC research community. The projects vary from karyotyping cell lines to development of FISH probes (including probes specific for canine chromosomes), identification of appropriate samples to test the probes and performing FISH on cell lines and archived specimens. From inception to date, 15 OSUCCC members have used the MCSR for 24 different projects representing all six OSUCCC programs and requiring over 2,000 hours of usage. Tools used have included SKY analysis of cell lines and patient samples, G-banded karyotyping of mouse and human tumors and various cell lines, FISH using several different probes and tissues for hybridization as well as development and labeling of some of the probes. An additional 22 projects have been identified for future service. Maintenance of high-standards, establishment and proper use of controls and control values and careful monitoring of all phases of investigation assure quality. It is expected that future use of the MCSR will continue to be extensive, as investigators have indicated continuing need for the services offered.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Denlinger, Nathan M; Epperla, Narendranath; William, Basem M (2018) Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Manag Res 10:615-624

Showing the most recent 10 out of 2602 publications